A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza

ClinicalTrials.gov ID: NCT02603952

Public ClinicalTrials.gov record NCT02603952. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a, Randomized, Partial Double-blind, Single Dose, Active-controlled, Dose Ranging Study to Evaluate the Safety of MEDI8852 in Adults With Acute, Uncomplicated Influenza

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate safety and tolerability of a single dose of MEDI8852 when given with oseltamivir, the safety and tolerability of oseltamivir alone, and the safety and tolerability of a single dose of MEDI8852 alone in adult participants with acute, uncomplicated influenza caused by Type A strains.

Study identification

NCT ID: NCT02603952
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: MedImmune LLC; Industry
Enrollment: 126 participants

Conditions and interventions

Conditions

Influenza

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 6, 2015
Primary completion: Dec 8, 2016
Completion: Dec 8, 2016
Last update posted: Jun 7, 2018

2015 – 2016

United States locations

U.S. sites: 22
U.S. states: 10
U.S. cities: 18

Facility	City	State	ZIP	Site status
Research Site	Canoga Park	California	91303	—
Research Site	Long Beach	California	90806	—
Research Site	Los Angeles	California	90017	—
Research Site	Upland	California	91786	—
Research Site	Hialeah	Florida	33012	—
Research Site	Hialeah	Florida	33013	—
Research Site	Hialeah	Florida	33016	—
Research Site	Miami	Florida	33165	—
Research Site	Miami	Florida	33173	—
Research Site	Miami	Florida	33185	—
Research Site	Miami Lakes	Florida	33014	—
Research Site	North Miami Beach	Florida	33162	—
Research Site	Avon	Indiana	46123	—
Research Site	Muncie	Indiana	47304	—
Research Site	New Orleans	Louisiana	70124	—
Research Site	Troy	Michigan	48085	—
Research Site	Butte	Montana	59701	—
Research Site	Hickory	North Carolina	28602	—
Research Site	Shelby	North Carolina	28150	—
Research Site	Smithfield	Pennsylvania	15478	—
Research Site	San Antonio	Texas	78229	—
Research Site	Clinton	Utah	84015	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02603952, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 7, 2018 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02603952 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →